AstraZeneca Heart Drug Proves Worthy, Elevating Sales Potential
This article is for subscribers only.
AstraZeneca Plc’s Brilinta reduces the risk of death from heart attack or stroke long after an initial attack, according to research that may bring billions of dollars to the company as more people use the drug for extended periods.
The anti-clotting medicine also was shown to work without causing an unacceptable level of bleeding, a key issue for blood thinners, the study team announced today at the American College of Cardiology’s annual meeting in San Diego.